Clinical trials: Visceral Obesity
Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT04964388
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Mississippi Medical Center
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
HIV Infections, Cardiovascular Disease
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood.
- Conditions
- HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy
- Trial name
- WU197 (NCT00656851)
- Testing
- Pioglitazone, Exercise Training
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Abdominal Obesity, Growth Hormone Deficiency
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular…
- Trial name
- NCT00675506
- Testing
- Growth hormone releasing hormone (GHRH) 1-44
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Morbid Obesity
Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Excess visceral fat is a key factor in the development of metabolic syndrome associated with obesity. After bariatric surgery, patients experience weight loss accompanied by a decrease in the amount of total body fat.
- Trial name
- NCT01285791
- Where
- Israel
- Volunteers
- 39 people
- Sponsor
- Hadassah Medical Organization
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Obesity, Visceral
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
This study is a clinical study to investigate the gluconeogenesis pathway related to visceral adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of empagliflozin (EMPA) on glucose homeostasis in…
- Trial name
- NCT02833415
- Testing
- [U-13C3] glycerol, Empagliflozin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Alcohol Drinking, Weight Loss
The Effects of Alcohol Consumption on Central Adiposity
The objective of the proposed study is to enroll women with obesity that will undergo a controlled, energy restricted feeding intervention to test the effects of chronic ethanol consumption on adipose distribution and circulating…
- Conditions
- Alcohol Drinking, Weight Loss, Adiposity, Obesity
- Trial name
- CONSUME (NCT03521817)
- Testing
- Alcohol, No Alcohol
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Obesity
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be…
- Trial name
- NCT00131378
- Testing
- Nutropin AQ growth hormone
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Obesity
Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Teenagers and adults who are overweight or obese have an increase in fat in the abdomen, which increases their risk for diabetes and heart disease.
- Trial name
- NCT01169103
- Testing
- recombinant human growth hormone (rhGH)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
Obesity, Visceral, Cardiovascular Diseases
Impact of Liraglutide 3.0 on Body Fat Distribution
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks…
- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Trial name
- NCT03038620
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Obesity, Metabolic Syndrome X
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions.
- Trial name
- REVIVE (NCT01351753)
- Testing
- Metformin, Orlistat, Topiramate
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Iowa
Metabolic Syndrome
Study of TNF-Antagonism in the Metabolic Syndrome (II)
This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.
- Trial name
- NCT00413400
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Hypertension
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and…
- Conditions
- Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity
- Trial name
- NCT00001723
- Testing
- Orlistat
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jack Yanovski
Obesity, Visceral, Obesity; Endocrine
Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
The Scope of this study is to assess the visceral and subcutaneous fat loss in patients having Tecar (Radiofrequency) Therapy and its effects on other anthropometric variables, adipokines and inflammation.
- Trial name
- NCT06377358
- Testing
- Tecar Therapy
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CAPENERGY MEDICAL, SL
Abdominal Obesity
Rosuvastatin in Visceral Adiposity
The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men.
- Trial name
- RIVIERA (NCT01068626)
- Testing
- Rosuvastatin
- Where
- Sweden
- Volunteers
- 54 people
- Sponsor
- Göteborg University